Review of atypical antipsychotics in anxiety

European Neuropsychopharmacology

Volumn 21, Issue 6, 2011, Pages 429-449

  Vulink, Nienke C C ^a   Figee, Martijn ^a   Denys, Damiaan ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Anxiety disorders; Atypical antipsychotics; Obsessive compulsive disorder

Indexed keywords

ARIPIPRAZOLE; CLOMIPRAMINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGORAPHOBIA; ANXIETY DISORDER; BIPOLAR DISORDER; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL PHOBIA; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; COMORBIDITY; HUMANS; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79955657782     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.12.007     Document Type: Review

References (87)

1. Adson D.E., Kushner M.G., Eiben K.M., Schulz S.C. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress. Anxiety 2004, 19:121-126.
2. Adson D.E., Kushner M.G., Fahnhorst T.A. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord. 2005, 86:99-104.
3. Ahearn E.P., Mussey M., Johnson C., Krohn A., Krahn D. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int. Clin. Psychopharmacol. 2006, 21:29-33.
4. Atmaca M., Kuloglu M., Tezcan E., Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2002, 17:115-119.
5. Bandelow B., Chouinard G., Bobes J., Ahokas A., Eggens I., Liu S., Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int. J. Neuropsychopharmacol. 2010, 13:305-320.
6. Barnett S.D., Kramer M.L., Casat C.D., Connor K.M., Davidson J.R. Efficacy of olanzapine in social anxiety disorder: a pilot study. J. Psychopharmacol. 2002, 16:365-368.
7. Bartzokis G., Lu P.H., Turner J., Mintz J., Saunders C.S. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol. Psychiatry 2005, 57:474-479.
8. Blin O., Azorin J.M., Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J. Clin. Psychopharmacol. 1996, 16:38-44.
9. Bogan A.M., Koran L.M., Chuong H.W., Vapnik T., Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J. Clin. Psychiatry 2005, 66:73-79.
10. Bogetto F., Bellino S., Vaschetto P., Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000, 96:91-98.
11. Brawman-Mintzer O., Knapp R.G., Nietert P.J. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry 2005, 66:1321-1325.
12. Brooke N.S., Wiersgalla M., Salzman C. Atypical uses of atypical antipsychotics. Harv. Rev. Psychiatry 2005, 13:317-339.
13. Buckley P.F., Goldstein J.M., Emsley R.A. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr. Res. 2004, 1(66(2-3)):143-150.
14. Butterfield M.I., Becker M.E., Connor K.M., Sutherland S., Churchill L.E., Davidson J.R. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int. Clin. Psychopharmacol. 2001, 16:197-203.
15. Bystritsky A., Ackerman D.L., Rosen R.M., Vapnik T., Gorbis E., Maidment K.M., Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J. Clin. Psychiatry 2004, 65:565-568.
16. Carey P.D., Vythilingum B., Seedat S., Muller J.E., van A.M., Stein D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 2005, 5:5.
17. Connor K.M., Payne V.M., Gadde K.M., Zhang W., Davidson J.R. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry 2005, 66:49-51.
18. D'Amico G., Cedro C., Muscatello M.R., Pandolfo G., Di Rosa A.E., Zoccali R., La Torre D., D'Arrigo C., Spina E. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:619-623.
19. Denys D., de G.F., van Megen H.J., Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 2004, 65:1040-1048.
20. Denys D., van Megen H., Westenberg H. Quetiapine addition to serotonin reputake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J. Clin. Psychiatry 2002, 63:700-703.
21. Diniz J.B., Shavitt R.G., Pereira C.A., Hounie A.G., Pimentel I., Koran L.M., Dainesi S.M., Miguel E.C. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J. Psychopharmacol. 2010, 24:297-307.
22. Donahue C.B., Kushner M.G., Thuras P.D., Murphy T.G., Van Demark J.B., Adson D.E. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J. Anxiety Disord. 2009, 23:362-368.
23. DSM-IV Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), 1994 1994, American Psychiatric Association.
24. Erzegovesi S., Guglielmo E., Siliprandi F., Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol. 2005, 15:69-74.
25. Fineberg N.A., Sivakumaran T., Roberts A., Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol. 2005, 20:223-226.
26. Fountoulakis K.N., Nimatoudis I., Iacovides A., Kaprinis G. Off-label indications for atypical antipsychotics: a systematic review. Ann. Gen. Hosp. Psychiatry 2004, 3:4.
27. Francobandiera G. Quetiapine augmentation of sertraline in obsessive-compulsive disorder. J. Clin. Psychiatry 2002, 63:1046-1047.
28. Gao K., Muzina D., Gajwani P., Calabrese J.R. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J. Clin. Psychiatry 2006, 67:1327-1340.
29. Glick I.D., Poyurovsky M., Ivanova O., Koran L.M. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J. Clin. Psychiatry 2008, 69:1856-1859.
30. Hamner M.B., Deitsch S.E., Brodrick P.S., Ulmer H.G., Lorberbaum J.P. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J. Clin. Psychopharmacol. 2003, 23:15-20.
31. Hirschfeld R.M., Weisler R.H., Raines S.R., Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2006, 67:355-362. for the BOLDER Study Group.
32. Hoge E.A., Worthington J.J., Kaufman R.E., Delong H.R., Pollack M.H., Simon N.M. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008, 13:522-527.
33. Hollifield M., Thompson P.M., Ruiz J.E., Uhlenhuth E.H. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress. Anxiety 2005, 21:33-40.
34. Jeste D.V., Dolder C.R. Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J. Psychiatr. Res. 2004, 38:73-103.
35. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress. Anxiety 2004, 20:44-47.
36. Katzman M.A., Vermani M., Jacobs L., Marcus M., Kong B., Lessard S., Galarraga W., Struzik L., Gendron A. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J. Anxiety Disord. 2008, 22:1480-1486.
37. Kellner M., Muhtz C., Wiedemann K. Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial?. J. Clin. Psychopharmacol. 2010, 30:471-473.
38. Klieser E., Wurthmann C., Czekalla J., Landefeld H., Lemmer W., Schulte T. Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low-dosages of the atypical antipsychotic. Eur. Neuropsychopharmacol. 2000, 10:344.
39. Koran L.M., Ringold A.L., Elliott M.A. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 2000, 61:514-517.
40. Kordon A., Wahl K., Koch N., Zurowski B., Anlauf M., Vielhaber K., Kahl K.G., Broocks A., Voderholzer U., Hohagen F. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol. 2008, 28:550-554.
41. Kozaric-Kovacic D., Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int. J. Neuropsychopharmacol. 2007, 10:253-261.
42. Littrell K.H., Petty R.G., Hilligoss N.M., Kirshner C.D., Johnson C.G. The effect of olanzapine on anxiety among patients with schizophrenia: preliminary findings. J. Clin. Psychopharmacol. 2003, 23:523-525.
43. Lohoff F.W., Etemad B., Mandos L.A., Gallop R., Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 2010, 30:185-189.
44. Maina G., Pessina E., Albert U., Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 2008, 8:364-372.
45. Matsunaga H., Nagata T., Hayashida K., Ohya K., Kiriike N., Stein D.J. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J. Clin. Psychiatry 2009, 70:863-868.
46. McDougle C.J., Barr L.C., Goodman W.K., Pelton G.H., Aronson S.C., Anand A., Price L.H. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am. J. Psychiatry 1995, 152:1812-1814.
47. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 2000, 57:794-801.
48. McIntyre A., Gendron A., McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 2007, 24:487-494.
49. Mello M.F., Costa M.C., Schoedl A.F., Fiks J.P. Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev. Bras. Psiquiatr. 2008, 30:358-361.
50. Menza M.A., Dobkin R.D., Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J. Clin. Psychopharmacol. 2007, 27:207-210.
51. Misri S., Milis L. Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J. Clin. Psychopharmacol. 2004, 24:624-627.
52. Mohr N., Vythilingum B., Emsley R.A., Stein D.J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 2002, 17:37-40.
53. Monnelly E.P., Ciraulo D.A., Knapp C., Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J. Clin. Psychopharmacol. 2003, 23:193-196.
54. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry 2005, 66(Suppl 8):13-21.
55. Padala P.R., Madison J., Monnahan M., Marcil W., Price P., Ramaswamy S., Din A.U., Wilson D.R., Petty F. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int. Clin. Psychopharmacol. 2006, 21:275-280.
56. Pessina E., Albert U., Bogetto F., Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int. Clin. Psychopharmacol. 2009, 24:265-269.
57. Petty F., Brannan S., Casada J., Davis L.L., Gajewski V., Kramer G.L., Stone R.C., Teten A.L., Worchel J., Young K.A. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int. Clin. Psychopharmacol. 2001, 16:331-337.
58. Pfanner C., Marazziti D., Dell'Osso L., Presta S., Gemignani A., Milanfranchi A., Cassano G.B. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int. Clin. Psychopharmacol. 2000, 15:297-301.
59. Pivac N., Kozaric-Kovacic D., Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl) 2004, 175:451-456.
60. Pollack M.H., Simon N.M., Zalta A.K., Worthington J.J., Hoge E.A., Mick E., Kinrys G., Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol. Psychiatry 2006, 59:211-215.
61. Prosser J.M., Yard S., Steele A., Cohen L.J., Galynker I.I. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry 2009, 26(9):25.
62. Ravizza L., Barzega G., Bellino S., Bogetto F., Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull. 1996, 32:677-682.
63. Reich D.B., Winternitz S., Hennen J., Watts T., Stanculescu C. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J. Clin. Psychiatry 2004, 65:1601-1606.
64. Robert S., Hamner M.B., Kose S., Ulmer H.G., Deitsch S.E., Lorberbaum J.P. Quetiapine improves sleep disturbances in combat veterans with PTSD: sleep data from a prospective, open-label study. J. Clin. Psychopharmacol. 2005, 25:387-388.
65. Saxena S., Wang D., Bystritsky A., Baxter L.R. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry 1996, 57:303-306.
66. Schutters S.I., van Megen H.J., Westenberg H.G. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J. Clin. Psychiatry 2005, 66:540-542.
67. Sepede G., De B.D., Gambi F., Campanella D., La R.R., D'Amico M., Cicconetti A., Penna L., Peca S., Carano A., Mancini E., Salerno R.M., Ferro F.M. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J. Clin. Psychopharmacol. 2006, 26:45-49.
68. Sevincok L., Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J. Clin. Psychopharmacol. 2003, 23:448-450.
69. Sheehan D.V., McElroy S.L., Harnett-Sheehan K., Keck P.E., Janavs J., Rogers J., Gonzalez R., Shivakumar G., Suppes T. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J. Affect. Disord. 2009, 115:376-385.
70. Simon N.M., Connor K.M., LeBeau R.T., Hoge E.A., Worthington J.J., Zhang W., Davidson J.R., Pollack M.H. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008, 197:675-681.
71. Simon N.M., Hoge E.A., Fischmann D., Worthington J.J., Christian K.M., Kinrys G., Pollack M.H. An open-label trial of risperidone augmentation for refractory anxiety disorders. J. Clin. Psychiatry 2006, 67:381-385.
72. Snyderman S.H., Rynn M.A., Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J. Clin. Psychopharmacol. 2005, 25:497-499.
73. Sokolski K.N., Denson T.F., Lee R.T., Reist C. Quetiapine for treatment of refractory symptoms of combat-related post-traumatic stress disorder. Mil. Med. 2003, 168:486-489.
74. Stathis S., Martin G., McKenna J.G. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J. Clin. Psychopharmacol. 2005, 25:539-544.
75. Stein M.B., Kline N.A., Matloff J.L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am. J. Psychiatry 2002, 159:1777-1779.
76. Stern R.G., Petti T.A., Bopp K., Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J. Clin. Psychopharmacol. 2009, 29:206-209.
77. Targum S.D., Abbott J.L. Efficacy of quetiapine in Parkinson's patients with psychosis. J. Clin. Psychopharmacol. 2000, 20:54-60.
78. Tohen M., Calabrese J., Vieta E., Bowden C., Gonzalez-Pinto A., Lin D., Xu W., Corya S. Effect of comorbid anxiety on treatment response in bipolar depression. J. Affect. Disord. 2007, 104:137-146.
79. Tollefson G.D., Sanger T.M., Beasley C.M., Tran P.V. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry 1998, 1(43(11)):803-810.
80. Uguz F. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen. Hosp. Psychiatry 2010, 32:556-558.
81. Vaishnavi S., Alamy S., Zhang W., Connor K.M., Davidson J.R. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1464-1469.
82. Villarreal G., Calais L.A., Canive J.M., Lundy S.L., Pickard J., Toney G. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol. Bull. 2007, 40:6-18.
83. Vulink N.C., Denys D., Fluitman S.B., Meinardi J.C., Westenberg H.G. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J. Clin. Psychiatry 2009, 70:1001-1008.
84. Weiss M., Baerg E., Wisebord S., Temple J. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Can. J. Psychiatry 1995, 40:205-207.
85. Wilner K.D., Anziano R.J., Johnson A.C., Miceli J.J., Fricke J.R., Titus C.K. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J. Clin. Psychopharmacol. 2002, 22:206-210.
86. Worthington J.J., Kinrys G., Wygant L.E., Pollack M.H. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 2005, 20:9-11.
87. Yargic L.I., Corapcioglu A., Kocabasoglu N., Erdogan A., Koroglu G., Yilmaz D. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int. J. Psychiatry Clin. Pract. 2004, 8:205-211.